Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Dynamic switching of apoptosis-modulating BIM heterodimers in response to BH3 mimetics in xenograft models of hematologic malignancies.

Molecular cancer therapeutics·2026

Same author

Endosialin (CD248) Cancer Role and Therapeutics: 33 Years on.

Molecular cancer therapeutics·2026

Same author

Alveolar soft-part sarcoma (ASPS) resembles a mesenchymal stromal progenitor: evidence from meta-analysis of transcriptomic data.

PeerJ·2020

Same author

UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor.

Journal of medicinal chemistry·2014

Same author

Gene expression profiling of 49 human tumor xenografts from in vitro culture through multiple in vivo passages--strategies for data mining in support of therapeutic studies.

BMC genomics·2014

Same author

Oxyphenisatin acetate (NSC 59687) triggers a cell starvation response leading to autophagy, mitochondrial dysfunction, and autocrine TNFα-mediated apoptosis.

Cancer medicine·2014

Same journal

Tracking Synthetic Adhesins on Bacterial Surfaces with Immunofluorescence Microscopy.

Methods in molecular biology (Clifton, N.J.)·2026

Same journal

Post-Selection Methods for Analyzing mRNA Display Selections and Optimization of Hits.

Methods in molecular biology (Clifton, N.J.)·2026

Same journal

High-Performance Computing in Tandem Mass Spectrometry (MS/MS) Peptide Identification.

Methods in molecular biology (Clifton, N.J.)·2026

Same journal

Engineering and Adapting Disulfide-Containing Proteins to Enable Intracellular Functionality.

Methods in molecular biology (Clifton, N.J.)·2026

Same journal

AI-Driven Protein Research: From Prediction to Design.

Methods in molecular biology (Clifton, N.J.)·2026

Same journal

Methods for the In Vitro Selection of Protein and Peptide Libraries Using mRNA Display.

Methods in molecular biology (Clifton, N.J.)·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 25, 2026

Characterization of Glycoproteins with the Immunoglobulin Fold by X-Ray Crystallography and Biophysical Techniques

Characterization of Glycoproteins with the Immunoglobulin Fold by X-Ray Crystallography and Biophysical Techniques

Published on: July 5, 2018

Anti-CD22 Onconase: preparation and characterization.

Dianne L Newton¹, Luke H Stockwin, Susanna M Rybak

¹NCI-Frederick, National Institutes of Health, Frederick, MD, USA.

Methods in Molecular Biology (Clifton, N.J.)

|March 3, 2009

Summary

This summary is machine-generated.

A novel antibody-drug conjugate, RFB4-Onconase, targets CD22+ lymphomas. This targeted therapy shows efficacy in preclinical models with low toxicity, offering a promising treatment for non-Hodgkin

More Related Videos

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)

Published on: September 17, 2019

Related Experiment Videos

Last Updated: Jun 25, 2026

Characterization of Glycoproteins with the Immunoglobulin Fold by X-Ray Crystallography and Biophysical Techniques

Characterization of Glycoproteins with the Immunoglobulin Fold by X-Ray Crystallography and Biophysical Techniques

Published on: July 5, 2018

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)

Published on: September 17, 2019

Area of Science:

Oncology
Immunotherapy
Biochemistry

Background:

Antibody-drug conjugates (ADCs) offer targeted delivery of cytotoxic agents.
Non-Hodgkin's lymphoma (NHL) expresses the CD22 antigen.
Onconase (Onc) is a ribonuclease with cytotoxic potential.

Purpose of the Study:

To develop a targeted therapeutic for CD22-expressing lymphomas.
To evaluate the efficacy and safety of RFB4-conjugated Onconase (RFB4-Onc).

Main Methods:

Conjugation of the anti-CD22 antibody RFB4 to Onconase.
Preclinical testing in lymphoma models.
Assessment of specificity and toxicity.

Main Results:

RFB4-Onc demonstrated enhanced specificity for CD22+ lymphomas.
Effective cytotoxicity was observed in preclinical models.
Minimal non-specific toxicities were noted in murine studies.

Conclusions:

RFB4-Onc is a potential drug candidate for non-Hodgkin's lymphoma.
Optimized derivatization and conjugation enhance therapeutic potential.
Targeted delivery of Onconase via RFB4 improves specificity and reduces toxicity.